Pharma channel feed – Endpoints News

Pharma channel feed

After EMA flop, Puma takes Nerlynx to China in new out-licensing deal

8 years ago

Nuclear scare to fuel anti-radiation drug sales? PTx buys ex-Sanofi drug just in case

8 years ago

Counting its remaining cash, Vical axes 40 staffers and circles wagons around two Phase II assets

8 years ago

Eyeing a multibillion-dollar market, Shire snags preclinical IVIg rival from AB Biosciences

8 years ago

Suspicious returns trigger insider trading suit following $11.6B Bioverativ deal

8 years ago

Roche scores an unusual ‘breakthrough’ at the FDA for an autism drug

8 years ago

In post-IPO party, Nasdaq’s newcomers Armo, Menlo and Solid soar within hours of listing

8 years ago

Novartis scores a quick FDA OK for its new cancer drug Lutathera, picked up in $4B buyout

8 years ago

Under pressure to perform, Woodford counterattacks against Sahm Adrangi's latest short assault

8 years ago

Biogen makes a buyout deal, but it’s not the big one you’ve been waiting for

8 years ago

Novartis steps in to grab ex-US rights to pioneering gene therapy Luxturna with $170M deal

8 years ago

Pfizer’s latest copycat could put the squeeze on Roche — again

8 years ago

Puma Biotechnology shares tank after CHMP looks ready to hit a red light on neratinib

8 years ago

J&J’s move to cut Remicade price cost some big bucks, but guarded against Pfizer’s copycat

8 years ago

FDA slaps down Braeburn on opioid addiction drug, putting Indivior and Alkermes in strong position

8 years ago

Government shutdown to end - at least temporarily - as Dems take McConnell at his word

8 years ago

Drugmakers take to Japan: 3 new drug approvals won by AstraZeneca, Merck, and EA Pharma

8 years ago

The next Emflaza: Acer Therapeutics looks to take a page out of Marathon's book

8 years ago

Insider trading scam spurred by $11.2B Gilead deal earns a stretch in prison

8 years ago

Novartis ties a new round of biosimilar development programs to a partnership deal with India's Biocon

8 years ago

Tired of being gouged for old, cheap therapies, a consortium of hospitals is going into the drug business — NYT

8 years ago

With Pfizer in hot pursuit, J&J loses a critical patent fight as it scrambles for a new prostate cancer drug OK

8 years ago

FDA and Pentagon forge breakthrough designation agreement

8 years ago

Merck KGaA taps UK cancer research organizations to feed pipeline

8 years ago

First page Previous page 308 309 310311312 313 314 Next page Last page